Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “PROSTATECTOMY”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 505 records · Page 28Linked to original sources
PubMed2005

[Radical perineal prostatectomy].

The authors have compared results of the first 9 perineal prostatectomies to a similar group of patients who underwent radical retropubic prostatectomy. In the group of patients after perineal prostatectomies the time of operation was at the average two hours less and the volume of blood loss was also two times less. Perineal radical prostatectomy is an effective modem method of treatment of localized prostate cancer. For many patients it will be a valuable alternative of the retropubic radical prostatectomy.

Aged↗
PubMed2006

Endoscopic extraperitoneal radical prostatectomy (EERPE): a new approach for treatment of localized prostate cancer.

UNLABELLED: Laparoscopic radical prostatectomy is usually performed by transperitoneal approach. Patients may encounter; intraperitoneal organs injury, and prolonged ileus during recovery period. The authors firstly performed endoscopic extraperitoneal radical prostatectomy (EERPE) in Thailand, which is mimicking open radical prostatectomy, the gold standard for treatment of localized prostate cancer. OBJECTIVE: Assess and evaluate the feasibility and early outcomes of the authors' experience in endoscopic extraperitoneal laparoscopic radical prostatectomy (EERPE). MATERIAL AND METHOD: From December 2005 to May 2006, 27 cases of EERPE were performed at the authors' institute for clinically localized prostate cancer by one surgeon (group I). Operative data was compared to those 55 patients who underwent open radical prostatectomy from February 2001 to August 2005 for early prostate cancer by the same surgeon (group II). Early postoperative results, clinical outcomes and complication were analyzed between the two groups using Chi-Square, student unpaired t-test and Mann-Whitney U tests. RESULTS: Patients' age and clinical staging were not different between the two groups. Mean operative time was longer in the EERPE group (268 minutes vs 157 minutes; p < 0.01). Median blood loss was 500 mls and 1000 mls in the EERPE and open groups, respectively (p < 0.001). The likelihood of transfusion rate in the open group was higher than the EERPE group, with odd ratio of 8.75 (95%CI = 2.09-39.86), p = 0.001. Hospitalization time and pathological stage were not different between the two groups. In the EERPE group, there were two rectal complications, including rectal injury and rectal necrosis, which were treated laparoscopically and conservatively without long-term problems. CONCLUSION: The authors' early experience has shown that EERPE is feasible. Although operative time was longer; the patients may gain benefit of minimally invasive surgery and decreased operative blood loss. In EERPE group, oncological outcomes are equal to open surgery, however more cases and long-term follow up are required to evaluate the efficacy of such an approach.

Aged↗
PubMed1989

Periurethral polytetrafluoroethylene injections for post-prostatectomy incontinence.

Incontinence following prostatectomy is relatively common and produces well-known social and pathologic consequences. Previous reports have shown that periurethral injections of polytetrafluoroethylene (PTFE or Teflon) can provide continence in many patients with a variety of etiologies. Politano's group has shown about 50% of his incontinence radical prostatectomy patients to be cured or improved by these injections. Our experience with 10 patients found that overall, six of 10 were cured or improved. Five of six radical prostatectomy patients were cured or improved after radical prostatectomy and radiation therapy. One patient has subsequently undergone artificial sphincter placement without difficulty. PTFE injections may be a low morbidity procedure for the treatment of post-prostatectomy incontinence and still allow for later artificial sphincter placement if required.

Humans↗
PubMed1995

[Is radical prostatectomy a suitable model for determination of PSA half-life?].

A review of the literature relating to PSA half-life reveals great variability in absolute values and pharmacokinetic models. A critical view is needed, however, since some authors suggest that the PSA half-life has implications for diagnosis and prognosis after radical prostatectomy. The aim of our study, therefore, was to characterize the value of PSA half-life determination after radical prostatectomy. Serial serum PSA detections were performed in 16 patients with localized prostatic cancer who had undergone radical prostatectomy. Serum PSA was detected on days 0, 1, 2, 3, 6, 9, 12, 15, 18, after radical prostatectomy. In all patients elimination of PSA from serum followed a biphasic logarithmic decay pattern indicating a two-compartment model of first order elimination kinetics (t1 = 1.01 +/- 0.06 days, t2 = 3.42 +/- 0.23 days; P < 0.00001). In this two-compartment model 56.3 +/- 4.8% of the preoperative PSA serum concentration was cleared by the first compartment. To find a biological correlative for the first compartment a mathematical model was developed to approximate the effect of operative blood and plasma loss on PSA serum concentration. In this model changes of hematocrit were used to estimate blood and plasma loss. These calculations showed that 50.12 +/- 3.04% of the preoperative PSA serum concentration was excreted by operative blood loss. This value was not significantly different from the clearance rate calculated for the first compartment. It is, therefore, concluded that the determination of PSA half-life after radical prostatectomy without correction of the operation-related PSA loss is only of limited value.

Adult↗
PubMed1994

[Laser prostatectomy as alternative to transurethral prostate resection in benign prostatic hyperplasia].

OBJECTIVE: Assessment of the results of laser prostatectomy, as a treatment for benign prostatic hyperplasia (BPH). DESIGN: Prospective case control study. SETTING: University Hospital Utrecht, the Netherlands. METHOD: Between February 1992 and May 1993, 54 men with their micturition complaints due to BPH were treated with laser prostatectomy (TULIP system). Results were assessed using the international prostatic symptom score (IPSS), the maximal flow and urodynamic tests. The results were compared retrospectively with results of transurethral resection of the prostate (TURP; n = 40): both groups were urodynamically identical. RESULTS: Of the 54 patients, 10 could not be evaluated 6 months after treatment (5 of them underwent TURP or a second laser prostatectomy). In 40 patients complete evaluation including urodynamics before and six months after treatment was possible. A significant decrease in the symptom score from 19.3 (SD: 7.6) to 6.3 (SD: 5.4) and increase of the maximal flow during pressure-flow studies from 9.6 to 15.8 ml per second were observed. The decrease of the voiding pressure at 6 months after TURP in comparison with laser prostatectomy was close to significance (p = 0.05); the other improvements after urodynamics were comparable. CONCLUSION: Laser prostatectomy is a promising new therapy for BPH.

Aged↗
PubMed1995

The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis.

Previous studies suggest that prostate cancer with a volume of 0.5 ml. or less and a Gleason score of less than 7 may be clinically insignificant and may be managed with watchful waiting. A proposed method of determining the volume of cancer in the prostate gland has been the grade and volume of cancer present in the transrectal needle biopsy specimen. Volume of cancer in the biopsy specimen as a predictor of volume of cancer in the prostate gland was studied in 130 men who underwent radical retropubic prostatectomy for adenocarcinoma. Of the men 46 (35%) had clinical stage T1c (nonpalpable) disease, while 84 (65%) had clinical stage T2 (palpable) disease. Each radical prostatectomy specimen was whole-mounted and step-sectioned for accurate cancer volume determination. Three parameters for measuring volume of cancer in the biopsy specimen (percentage of biopsy cores involved, millimeters of cancer per biopsy core and percentage of cancer in the biopsy specimen) were determined and compared by Spearman rank correlation analysis. The percentage of cancer in the biopsy specimen was marginally better than the percentage of cores involved and the millimeters of cancer per biopsy core as a predictor of cancer volume in the radical prostatectomy specimen. While regression analysis revealed a direct correlation between the volume of cancer in the biopsy and radical prostatectomy specimens (r = 0.51), there was significant variability in prostate cancer volume for a given percentage of cancer in the biopsy specimen since the standard error of the estimate was 6.1 ml. Of the 13 patients with 5% or less cancer volume and a Gleason score of less than 7 in the biopsy specimen 1 (8%) had a cancer smaller than 0.5 ml. in volume in the radical prostatectomy specimen. Therefore, the risk of removing clinically insignificant prostate cancer, even when the biopsy parameter indicates low volume disease, is less than 10%. Overall, only 3 study patients (2.3%) had a prostate cancer volume of less than 0.5 ml. With 97.7% of the men having a clinically significant cancer by a volume criterion, it is apparent that the majority of clinically insignificant prostate cancers remained undetected and untreated. Currently, transrectal needle biopsy does not provide adequate information for differentiating between clinically insignificant and life threatening prostate cancer on an individual basis.

Adenocarcinoma↗
PubMed1993

Detrusor contraction strength in men undergoing prostatectomy.

Elective prostatectomy is a frequently performed operation but the outcome may not always be satisfactory. This is probably because a significant number of men, despite subjective symptoms, are not urodynamically obstructed before operation and the preoperative assessment of obstruction is not easy using conventional urodynamic criteria. We have calculated detrusor contraction strength (WF) in men before and after prostatectomy. Our aim was to determine its relationship with symptomatic and urodynamic findings before and after prostatectomy and whether it was associated with clinical outcome. One hundred and twenty nine men listed for operation because of symptoms and low urinary flow rates were studied by means of urodynamic investigation and symptom scoring both before and 6 months after prostatectomy. A significant association was found between persistent obstructive symptoms after operation and a low WF before operation (P = 0.01), suggesting that weak detrusor function before operation was the cause of persistent symptoms afterwards. A significant correlation was also found between a high pre-operative WF and a high post-operative urinary flow rate; (P = 0.003); men with high detrusor power achieving the better flow rates after operation. Despite this relationship, the overall subjective clinical outcome was not strongly associated with WF and WF was no better than simple measurement of voiding pressure in predicting outcome in a multivariate analysis. The measurement of detrusor contraction strength provides some insight into the relationship between bladder function and clinical outcome after prostatectomy, but we have found it unable to predict outcome for the individual patient.

Aged↗
PubMed1994

[Radical prostatectomy: comparison of the perineal and retropubic route (40 patients). Preliminary results].

Transperineal radical prostatectomy, described at the beginning of the century for the treatment of prostatic cancer, is currently being reappraised following the development of surgical techniques allowing the dissection of subvenous external iliac nodes via a limited incision. Twenty four patients (group 1) underwent transperineal prostatectomy and 16 (group 2) underwent retropubic prostatectomy. The choice of surgical approach was left to the operator. We retrospectively compared the two groups. All patients had histologically proven prostatic cancer, clinically confined to the prostate. The operating time, the development of complications. the preoperative-postoperative haemoglobin difference, the number of patients transfused and the number of units transfused, urinary continence at three months and the histological results were studied. Three patients operated via the perineal approach and one patient operated via the retropubic approach suffered an operative rectal injury. The number of transfused patients (12.5% in group 1 and 37.5% in group 2) and the preoperative-postoperative haemoglobin difference for non-transfused patients (mean of 2.9 g/100 ml in group 1 vs 4.6 g/100 ml in group 2) were significantly different. No significant difference was observed between the two groups in terms of invasion of the prostatic capsule or seminal vesicles. Overall, only 106 out of 40 patients had a truly intraprostatic tumour, corresponding to understaging of the cancer in 60% of cases. Although the number of patients with imperfect continence was higher in group 1, the difference observed was not significant. The transperineal approach allows prostatectomy to be performed under similar oncological conditions to those of retropubic prostatectomy, while decreasing the operative blood loss.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗
PubMed1995

Current results and patient selection for nerve-sparing radical retropubic prostatectomy.

The anatomical radical retropubic prostatectomy currently may be performed with low morbidity and mortality. The nerve-sparing aspect of the anatomical radical retropubic prostatectomy has allowed preservation of potency in the majority of men with localized prostate cancer. Overall potency rates of up to 71% may be achieved without compromising the complete eradication of cancer. Prostate cancer control with nerve-sparing surgery is similar to that reported for the standard radical retropubic prostatectomy. Inaccurate clinical staging of prostate cancer and the inability to determine tumor involvement of the neurovascular bundle have made it difficult to decide with certainty preoperatively which patients should undergo preservation versus wide excision of the neurovascular bundle. Some of the controversies that may determine utility of nerve-sparing radical prostatectomy include the impact of prostate cancer capsular penetration and positive surgical margins on tumor progression and patient survival. The selection of the ideal patient who has clinically localized prostate cancer for nerve-sparing radical prostatectomy has been improved by using as guidelines such preoperative factors as serum prostate-specific antigen tumor grade and the presence of perineural invasion on biopsy, and by using tumor location and volume to help predict true pathological stage. Other preoperative studies including transrectal ultrasound, computed tomography, and magnetic resonance imaging are generally not helpful.

Erectile Dysfunction↗
PubMed1996

Cost-efficient radical prostatectomy with a clinical care path.

PURPOSE: We assessed changes in hospital costs and resource use among patients undergoing radical prostatectomy following implementation of a clinical care path. MATERIALS AND METHODS: A standardized clinical care path for patient management before and after radical prostatectomy was developed and implemented at a large academic medical center in California. All 577 consecutive patients undergoing radical prostatectomy during the 3 years before and 1 year after implementation of the care path were included in the study. Each patient was entered prospectively into a hospital-wide financial data base, which served as the source for observations on hospital costs, hospital charges and length of stay. RESULTS: After implementation of the radical prostatectomy care path hospital costs decreased by 12% ($7,916 versus $6,934, p < 0.001), hospital charges decreased by 20% ($17,005 versus $13,524, p < 0.0001) and length of stay decreased by 28% (5 versus 3.6 days, p < 0.0001). Decreases were noted in all categories of the hospital patient financial profile, except operating room charges. CONCLUSIONS: By standardizing preoperative and postoperative management for patients undergoing radical prostatectomy, significant savings can be achieved over and above existing trends toward shorter hospital stays and lower hospital costs.

Aged↗
PubMed1996

Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer.

PURPOSE: We determined whether 12 weeks of neoadjuvant testicular androgen ablation therapy using a luteinizing hormone-releasing hormone agonist could improve pathological outcomes in men undergoing radical retropubic prostatectomy for clinically localized (stages T1C, T2A and T2B) prostatic carcinoma. MATERIALS AND METHODS: A total of 56 participants was randomized to receive either monthly injections of a luteinizing hormone-releasing hormone agonist at 4-week intervals followed by radical retropubic prostatectomy (28) or to undergo immediate radical retropubic prostatectomy alone (28). Operations were performed via similar technique and all prostatic specimens were processed histologically in their entirety. RESULTS: There was no improvement in pathological outcome using luteinizing hormone-releasing hormone agonist preoperatively compared to surgery alone. Of 28 men undergoing immediate radical retropubic prostatectomy 23 had organ-confined (17) or specimen-confined (6) disease versus 22 of 28 who received luteinizing hormone-releasing hormone neoadjuvant therapy for 12 weeks preoperatively (16 with organ-confined and 6 with specimen-confined disease, p = 1.00). In addition, when the study population was analyzed by pretreatment prostate specific antigen (PSA) levels (10 ng./ml. or less, or greater than 10 ng./ml/) there was also no difference in pathological outcome (p = 0.65 for PSA greater than 10 and p = 0.32 for PSA less than 10). CONCLUSIONS: Neoadjuvant androgen ablation therapy for 12 weeks before radical prostatectomy in patients with clinically localized adenocarcinoma of the prostate does not result in improved pathological outcomes.

Adenocarcinoma↗
PubMed1996

Urodynamic assessment of urethral sphincter function in post-prostatectomy incontinence.

PURPOSE: Direct measurement of maximum urethral pressure by urethral profilometry has been used widely to assess urethral sphincter function. We attempted to determine if there was any relationship between maximum urethral pressure, which is measured at the level of the membranous urethra, or extrinsic urethral sphincter function, and the amount of abdominal pressure needed to cause leakage (abdominal leak point pressure) in men with post-prostatectomy incontinence. We also examined the relationship between external sphincter function and continence or incontinence. MATERIALS AND METHODS: We retrospectively evaluated fluoro-urodynamics performed in 37 men with post-prostatectomy incontinence. Urodynamic study consisted of measurement of maximum urethral and abdominal leak point pressures, and assessment of extrinsic sphincter function by pressure measurements and radiographically. RESULTS: Data were analyzed on 27 patients for whom abdominal leak point and maximum urethral pressures were available. Mean maximum urethral pressure was 52.5 cm. water (range 20 to 165) and mean abdominal leak point pressure was 77.8 cm. water (range 27 to 132). Regression analysis was performed between maximum urethral and abdominal leak point pressures. A Pearson correlation coefficient of 0.13834 was calculated (p = 0.4914) indicating virtually no correlation between the 2 measurements in our sample. Extrinsic urethral sphincter was normal in all patients. Only 1 of 37 patients had no evidence of intrinsic sphincter deficiency, that is there was no urine leakage with increases in abdominal pressure and the patient was incontinent solely based on bladder dysfunction (detrusor instability). CONCLUSIONS: Our study indicates that incontinence after prostatectomy due to an increase in abdominal pressure (stress incontinence) does not depend on extrinsic sphincter function and is not related to maximal urethral pressure. We conclude that post-prostatectomy incontinence due to sphincter dysfunction results from intrinsic sphincter deficiency. In our experience bladder dysfunction is rarely the sole cause of post-prostatectomy incontinence.

Aged↗
PubMedDate not supplied

[Detailed evaluation of sexual function after radical prostatectomy: is patient satisfaction correlated with the quality of erections?].

INTRODUCTION: Post radical prostatectomy potency rates, quantified on the basis of physician survey, have ranged up to 80%. Physician derived potency data, however, may not be representative of true post-prostatectomy potency rates or more importantly may not accurately portray patients' post-operative sexual satisfaction. We conducted a pilot study combining physician derived and patient derived subjective data with objective measures of erectile function. MATERIALS AND METHODS: Eleven men, mean age of 59 years, who were treated with nerve sparing radical retropubic prostatectomy formed the study group. Initially, the patients responded to a physician directed telephone survey on sexual status. Potency was then objectively assessed utilizing Rigiscan testing on two consecutive evenings. Lastly, the patients completed a validated short questionnaire directed to obtain a patients' subjective perception of sexual function. RESULTS: All the patients responded to the first part of the study by informing the physician that they were sexually active or potent after radical prostatectomy. Of these 11 patients, however, only 2 (18%) were mostly satisfied with their sex life according to the quality of life questionnaire. Rigiscan testing revealed that 8 of the 11 patients had nocturnal erections which were adequate for vaginal penetration. Of the 5 patients who stated that they were mostly dissatisfied with their sexual functioning, 3 had objective evidence of adequate erectile ability as documented by Rigiscan. Three of the four patients who were ambivalent with respect to their sexual function also demonstrated objective evidence of normal erectile activity. CONCLUSION: Although a patient may inform his care provider that he is sexually active or potent, he may not be satisfied with his present level of sexual functioning. In addition, we observed that some dissatisfied patients do have normal Rigiscan patterns indicating that a percentage of patients who are not happy with their level of sexual function after radical prostatectomy may have a psychogenic component to their problem.

Aged↗
PubMed1996

Techniques of coagulation laser prostatectomy for narrow divergence angle fibers.

Although laser prostatectomy has become an accepted technique for the treatment of obstructive prostatism, considerable debate remains about which laser prostatectomy method to use in various treatment situations. This article discusses the different methods of noncontact side-firing coagulation laser prostatectomy using narrow divergence angle fibers (< 30 degrees). Static treatment strategies that have been successfully employed with widely divergent beams are not appropriate for fibers producing narrow divergence angle beams. Narrow divergence angle beams produce a small diameter spot on the prostatic urethra and far larger power density. Additionally, neodymium/yttrium aluminum garnet light scatters relatively poorly within prostatic tissue. Most light continues along the path of through transmission until ultimate tissue absorption and conversion into heat. The width and total volume of the coagulated lesion is therefore limited when using a narrow divergence angle fiber to produce static lesions. Probe movement is essential. Rapid (> 2 mm/s) probe movement produces only superficial coagulation. An initial dwell period of approximately 3 s is also important to maximize coagulated tissue volume. Scanning strategies where the fiber is moved through the prostatic urethra in longitudinal and radial directions are discussed and compared. Radial and longitudinal scanning methods produce similar coagulation defects. Treatment using a rocking motion within a limited volume of tissue may increase coagulation depth. No technique is ideal for all clinical situations. Vaporization prostatectomy or contact laser transurethral incision of the prostate is appropriate for primary treatment of glands < 30 g or as adjunctive therapy to facilitate early catheter removal. Alternative treatment methods are compared to noncontact coagulation prostatectomy.

Humans↗
PubMed1997

Survival after radical prostatectomy.

CONTEXT: The generalizability of currently available estimates of survival after radical prostatectomy is theoretically limited. OBJECTIVE: To obtain generalizable estimates of survival after radical prostatectomy. DESIGN: A population-based retrospective cohort study. SETTING: Nine regions of the United States. PATIENTS: Patients who were diagnosed with prostate cancer between 1983 and 1987 and underwent radical prostatectomy and lymph node dissection. MAIN OUTCOME MEASURES: Proportional hazards models incorporating geographical region, age, race, pathological stage, lymph node involvement, and tumor grade to identify independent correlates of disease-specific and overall survival and life table analyses to estimate 10-year survival distributions. RESULTS: A total of 3626 patients with a mean age of 65 years were included in the study; 92.6% were white, 54.2% had moderate-grade cancer, 60.4% had no extension beyond the prostate, and 91.2% had no lymph node involvement. Using San Francisco-Oakland, Calif, as a reference region, no other region was significantly associated with a risk of disease-specific or overall mortality. Older age and black race were independently associated with worse overall but not disease-specific survival. Higher grade, extension beyond the prostate, and lymph node involvement were independently associated with worse disease-specific and overall survival. Estimates of 10-year disease-specific survival ranged from 75% to 97% for patients with well-differentiated and moderately differentiated cancers and from 60% to 86% for patients with poorly differentiated cancers. CONCLUSIONS: Neither disease-specific nor overall survival varied by region, suggesting geographically uniform assessments of risk in patient selection for radical prostatectomy. Across regions, overall survival varied by patient and prostate cancer characteristics while disease-specific survival varied substantially by prostate cancer but not patient characteristics. The present analyses provide the most generalizable current estimates of survival after radical prostatectomy.

Aged↗
PubMed1997

[Clinical outcome of radical prostatectomy for stage C prostate cancer: comparison with other treatment modalities].

Of the 69 patients with clinical stage C prostate cancer under 75 years old and with good performance status between 1986 and 1995, 29 underwent radical prostatectomy combined with endocrine therapy, 21 underwent radiation therapy combined with endocrine therapy and remaining 19 patients were treated by endocrine therapy alone. The median followup was 44 months (range 4 to 122). Radical prostatectomy resulted in progression-free rates of 79% and 61% at 5 and 10 years, respectively. Progression-free rates were lower in patients with lymph node metastasis or positive surgical margins. In patients with clinical stage T3a-c and well or moderately differentiated tumor, radical prostatectomy resulted in a progression-free rate of 100% at 5 years. However, in patients with clinical stage T4a or poorly differentiated tumor, radiation therapy resulted in a better progression-free rate than radical prostatectomy. These findings suggest that patients with clinical stage T3a-c and well or moderately differentiated tumor will benefit from radical prostatectomy combined with endocrine therapy and that radiation therapy well be effective for advanced diseases.

Aged↗
PubMed1997

[Radical retropubic prostatectomy].

Radical prostatectomy may cure most patients in whom the malignant tumor has not invaded through the prostatic capsule. Advances in surgical technique and accumulation of experience have decreased the complication rate significantly. Long-term results of surgical treatment are now better than those of other forms of treatment; hence radical prostatectomy is now recommended for men with life expectancies longer than 10 years. Between 1988 and 1995, 164 men with clinical stages T1 or T2 adenocarcinoma were admitted for radical prostatectomy. Most were not offered a nerve-sparing procedure, so as to allow wider, more complete resection. Those who wanted preservation of sexual function underwent the nerve- preserving procedure. In 6 patients operation was discontinued when metastases to the mac lymph nodes were detected and in 1 when invasion of the pelvic wall was found, 157 underwent radical prostatectomy. Preoperative biopsy revealed a low-grade lesion (Gleason 2-4) in 19.1%, intermediate grade (Gleason 5-6) in 61.8% and high-grade (Gleason 7-9) in 19.1%; however, pathologic grading revealed that only 7.0% had grade 2-4 tumor, 60.5% grade 5-6 and 32.5% grade 7-9. Pathologic staging revealed T2 tumor in 58%, T3 in 38.8% (including microscopic invasion of the capsule or seminal vesicles); microscopic lymph node metastases were found in 3.2%. Tumor invasion through the capsule was found in only 2 of 13 treated with neoadjuvant androgen blockade, compared with 40% in those who did not receive this treatment. There was no operative mortality and only 14.7% has complications. All had urinary incontinence immediately after operation, but regained continence after an average of 4-5 months, 24 were incontinent for more than 12 months, but most of them had only mild stress incontinence. Most patients were impotent after the procedure. There was tumor recurrence, diagnosed by rise in serum PSA, in 26 during an average followup of 26.4 months (range 3-93). Cure rate of prostatic cancer by radical prostatectomy may be increased by improved preoperative staging methods and better patient selection; long term follow up is required for determining cure rate.

Aged↗
PubMed1997

Use of partial prostatectomy for treatment of prostatic abscesses and cysts in dogs.

OBJECTIVE: To determine whether dogs had prostatic disease, urinary incontinence, or urinary tract infection 1 year after partial prostatectomy to treat prostatic abscesses and cysts. DESIGN: Prospective study. ANIMALS: 20 male dogs with prostatic abscesses or cysts. Fifteen dogs had evidence of urinary tract infection. Only 8 dogs urinated normally; the remainder dribbled, had obstructions, or required medical treatment. PROCEDURE: Partial prostatectomy was performed on each dog. Sexually intact dogs (n = 12) also were castrated. RESULTS: None of the dogs had return of prostatic cystic enlargement or clinical signs of prostatic disease during the first year after surgery. Two dogs were euthanatized within 1 year after surgery, with 1 dog having prostatic enlargement and adenocarcinoma and 1 dog having unrelated lymphosarcoma. Fifteen dogs were continent. The remaining 5 dogs urinated normally but had intermittent and minor incontinence. Eleven dogs had no signs of infection 1 year after surgery, 5 had pyuria or positive urine bacteriologic culture results, 2 did not have urinalysis performed, and 2 were euthanatized. CLINICAL IMPLICATIONS: Dogs with severe prostatic abscesses or cysts and infections can be successfully treated by partial prostatectomy with an ultrasonic surgical aspirator and castration, resulting in long-term disease resolution. Although most dogs with severe prostatic disease do not urinate normally before surgery, nearly all dogs resume normal micturition after partial prostatectomy. Postoperative results of partial prostatectomy appear to be better than those of previous drainage techniques for treatment of prostatic cavitary disease.

Abscess↗